Saturday 17 October 2026
Export NSPR’s income statement to Excel — free account
InspireMD, Inc.
NSPR Healthcare Medical Devices
InspireMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 28.1% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 34.6% and free cash flow fell 26.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
0.46
0.02
−4.17%
Follow NSPR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.47 | 12.59 | 12.75 | 22.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.44) | (11.07) | (12.25) | (20.51) | |
P/B ratio |
1.88 | 3.13 | 2.07 | 2.76 | |
Price to Tangible BV |
1.88 | 3.13 | 2.08 | 2.76 | |
EV/Sales |
3.01 | 9.11 | 7.14 | 15.10 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.79) | (2.56) | (1.83) | (3.61) | |
EV/FCF |
(0.77) | (2.46) | (1.74) | (3.45) | |
Quick Ratio |
3.40 | 4.70 | 5.30 | 6.09 | |
Current Ratio |
3.80 | 5.15 | 5.74 | 6.51 | |
Net Debt/EBITDA |
2.13 | 3.01 | 4.54 | 4.91 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.28 | 0.23 | 0.15 | 0.12 | |
Operating CF/Net income |
0.76 | 0.90 | 0.79 | 0.68 | |
Capex/Depreciation |
(2.09) | (1.30) | (2.78) | (2.45) | |
Research and Development Expense of Revenue |
242.52% | 140.17% | 110.35% | 144.07% | |
Selling, General and Administrative Expense of Revenue |
529.42% | 291.41% | 310.86% | 407.45% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
125.24% | 61.95% | 90.44% | 140.47% | |
Graham Net Nets |
0.40 | 0.26 | 0.41 | 0.32 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(91.43%) | (44.79%) | (44.38%) | (34.85%) | |
Free Cash Flow Yield |
(71.62%) | (29.38%) | (32.10%) | (19.24%) | |
Revenue per Share |
0.02 | 0.04 | 0.05 | 0.03 | |
Operating CF per Share |
(0.13) | (0.15) | (0.15) | (0.12) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.15) | (0.15) | (0.12) | |
Cash per Share |
0.36 | 0.50 | 0.84 | 0.86 | |
Shareholders Equity per Share |
0.37 | 0.52 | 0.86 | 0.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.37 | 0.52 | 0.86 | 0.87 | |
Free Cash Flow |
(11.22) | (12.53) | (9.74) | (8.95) | |
Working Capital |
26.98 | 39.15 | 50.76 | 59.58 | |
Capital Expenditures |
(0.33) | (0.19) | (0.40) | (0.31) | |
Net Current Asset Value |
23.50 | 35.74 | 47.27 | 56.03 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.19 | 0.06 | 0.13 | 0.12 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.25 | 2.57 | 2.41 | 2.35 | |
Average Payables |
9.36 | 8.41 | 9.20 | 9.04 | |
Average Inventory |
2.88 | 2.93 | 2.98 | 3.03 | |
Average Assets |
38.99 | 47.57 | 58.11 | 64.48 | |
Average Common Equity |
25.88 | 35.98 | 45.64 | 52.73 |
Columns are period end dates